Few compounds in the modern nootropics world generate as much curiosity — and as much hype — as flmodafinil. Known in research circles by the development code CRL-40,940 (and a string of other names: NLS-4, JBG01-41, bisfluoromodafinil, lauflumide), it is frequently marketed as a “next-generation” eugeroic: a fluorinated cousin of modafinil that promises sharper wakefulness at a fraction of the dose. The molecule is genuinely interesting from a chemistry standpoint, and the community enthusiasm around it is real. But so is the responsibility to be honest about what we actually know. This in-depth guide explains what flmodafinil is, how it is thought to work, how it compares to modafinil, armodafinil and adrafinil, and — crucially — where the evidence is solid versus where it is preliminary, anecdotal or simply unproven. NeuroPeak’s view is straightforward: a compound this under-studied deserves clear, balanced information rather than marketing gloss.
What is flmodafinil?
Flmodafinil is a synthetic wakefulness-promoting agent — a class of compound known as a eugeroic — and a close structural analogue of modafinil. Chemically, it is the bis(4-fluorophenyl) version of modafinil, with the molecular formula C15H13F2NO2S and a molar mass of roughly 309.33 g/mol. The “fl” in its name refers to the two added fluorine atoms, and “modafinil” signals its parentage. You will see it referred to interchangeably as CRL-40,940, NLS-4, lauflumide or bisfluoromodafinil; these are all the same molecule.
Its lineage traces back to Lafon Laboratories — the French company, founded by chemist Louis Lafon, that originally developed modafinil itself. Flmodafinil was advanced more recently by NLS Pharmaceutics AG, with the compound credited to inventor Eric Konofal. It was patented in 2013 (US patent application US20130295196) and entered formal preclinical research around December 2015, where it was explored for indications including chronic fatigue, idiopathic hypersomnia, narcolepsy, ADHD and Alzheimer’s-related cognitive decline.
Here is the first important honesty note, and it frames everything that follows: as of 2025 there are zero published, peer-reviewed human clinical trials of flmodafinil. There are no human pharmacokinetic studies, no efficacy trials and no formal human safety data in the public literature. It is not approved by the EMA, the FDA, the MHRA or any other regulator, for any purpose. In fact, NLS Pharmaceutics has reportedly deprioritised flmodafinil development for narcolepsy, ADHD and Alzheimer’s, with only chronic-fatigue-type interest noted as remaining preclinical as of early 2024 — its active clinical pipeline now centres on a different compound (mazindol ER, branded Quilience). Online, flmodafinil is sold as a grey-market “research chemical”. Keep that context in mind as we explore the science.
The chemistry of fluorination
The defining feature of flmodafinil is the substitution of two fluorine atoms at the para positions of modafinil’s two phenyl rings. This may sound like a minor tweak, but in medicinal chemistry, strategic fluorination is a well-established way to alter a molecule’s behaviour — which is why fluorine appears in a remarkable proportion of modern pharmaceuticals.
Adding fluorine tends to do two things here. First, it increases lipophilicity (fat-solubility), which in theory improves a molecule’s ability to cross the blood-brain barrier and reach the central nervous system. Second, the carbon-fluorine bond is exceptionally stable, so fluorination is often used to increase metabolic resistance — slowing the rate at which liver enzymes break the molecule down. The patent claims for flmodafinil lean on exactly these ideas: greater stability, and by extension greater per-milligram potency and a longer-lasting effect.
It is worth being precise about confidence levels. The structural fact — two fluorines on the phenyl rings — is high-confidence and well-documented. The functional interpretation (“therefore it is more potent and longer-lasting in humans”) is more tentative. It is biologically plausible and partly supported by in-vitro binding data and rodent studies, but a meaningful chunk of it comes from patent language rather than independent human research. Plausible is not the same as proven, and that distinction matters when you are deciding what to put in your body.
How it works — mechanism of action
Flmodafinil’s presumed mechanism is shared with modafinil. The primary action is as a selective, atypical dopamine reuptake inhibitor: it binds to the dopamine transporter (DAT) and reduces the reabsorption of dopamine, raising dopamine levels in key brain regions associated with arousal, motivation and focus. The “atypical” part is important — flmodafinil binds DAT in a way that produces a gentler, more gradual rise in dopamine than classic stimulants like amphetamine, which is the pharmacological basis for the modafinil class’s notably low abuse-liability profile.
Published in-vitro binding data give flmodafinil a reported DAT affinity (Ki) of around 4,090 nM, slightly stronger than armodafinil’s roughly 5,480 nM. Its individual enantiomers differ: the S-form (JBG1-048) shows a Ki of about 2,970 nM and the R-form (JBG1-049) about 4,830 nM. Affinity for the serotonin transporter is far weaker (SERT Ki ~48,700 nM, roughly twelve times weaker than DAT), and sigma-1 receptor binding is negligible (Ki >100,000 nM). These are real published numbers — but they come from laboratory assays, not human dosing, and receptor pharmacology does not automatically translate into clinical benefit.
Beyond dopamine, modafinil is understood to have downstream effects on the brain’s orexin (hypocretin) and histamine wakefulness pathways, both of which help keep us alert. It is widely assumed that flmodafinil shares these effects — but this is inference by analogy, not something demonstrated directly for flmodafinil in published work. Treat the orexin/histamine story as a reasonable hypothesis rather than an established fact.
The single strongest piece of primary evidence is a 2018 rat study published in the European Journal of Neuroscience (PMC8294075). Using brain microdialysis, researchers found that flmodafinil’s enantiomers raised dopamine in the nucleus accumbens shell to roughly 220–308% of baseline, comparable to or somewhat greater than R-modafinil, and — notably — the elevation lasted longer (around 200% of baseline still present about an hour post-dose, versus a faster fall-off for modafinil). Reassuringly, the dopamine increases were far below those produced by cocaine or amphetamine, consistent with the low-abuse-liability picture. This is genuinely useful data — but it describes rodent neurochemistry, not proven human cognitive enhancement.
Sublingual delivery — why it matters
NeuroPeak’s flmodafinil 50mg sublingual solution uses a sublingual (under-the-tongue) format rather than a tablet, and there is a sensible rationale behind that choice. The tissue beneath the tongue is rich in blood vessels, so substances held there can be absorbed directly into the bloodstream, partially bypassing first-pass metabolism in the liver and gut.
In principle, sublingual delivery offers a faster onset and potentially more consistent absorption than swallowing a capsule, which must survive the digestive tract before reaching circulation. A liquid format also allows for finer, more flexible dose titration — useful for a compound where the appropriate amount is still being worked out by the community. We should keep this measured, though: the specific human pharmacokinetics of flmodafinil by any route remain uncharacterised in the literature. The sublingual advantage is a well-established principle in pharmacology generally, not a flmodafinil-specific clinical finding.
Flmodafinil vs modafinil — detailed comparison
The most common question is simply: how does flmodafinil stack up against the established benchmark, modafinil? The honest answer is that flmodafinil is positioned as a refined version, but the comparison is heavily weighted by the fact that one is an approved, extensively studied medicine and the other is an unapproved research chemical. Figures marked (estimated) below are derived from preclinical data, patent claims or user anecdote — they are not established human values.
| Attribute | Flmodafinil (CRL-40,940) | Modafinil |
|---|---|---|
| Chemical class | Bis(4-fluorophenyl) analogue of modafinil | Original eugeroic / parent compound |
| Regulatory status | Unapproved; sold as a “research chemical” | Approved prescription medicine in many countries |
| Human clinical data | None published | Extensive RCTs and long-term safety data |
| DAT affinity (Ki, in vitro) | ~4,090 nM | Comparable (armodafinil ~5,480 nM) |
| Reported per-mg potency | Claimed higher; users dose ~25–50% of a modafinil dose (estimated) | Reference standard |
| Typical dose discussed | ~25–100 mg (estimated, no validated dose) | 100–200 mg (clinically established) |
| Half-life / duration | Unknown in humans; often quoted ~12–15 h by extrapolation (estimated) | ~12–15 h (measured) |
| Duration of dopamine effect | Longer in rats (~200% baseline at 1 h) (preclinical) | Faster offset in the same rat study |
| CYP450 induction | Reportedly does not induce CYP450 (preclinical/patent) | Induces CYP enzymes (real drug interactions) |
| Abuse liability signal | Low (rodent dopamine far below stimulants) | Low (well documented) |
The headline marketing lines you will encounter — “2–3x more potent”, “40% longer-lasting”, “cleaner”, “fewer side effects” — all sit in that (estimated) column. They are not falsehoods exactly, but they are not established in humans either. They originate from rodent neurochemistry, in-vitro binding, patent claims and user reports. They may well translate to human experience; they may not. For a deeper look at the established eugeroics, our modafinil vs armodafinil comparison covers two compounds with genuine human evidence behind them.
Reported effects and benefits
Because there are no controlled human trials, everything in this section reflects anecdotal and vendor-sourced reports rather than clinical findings. With that firmly stated, users of flmodafinil commonly describe:
- Increased wakefulness and reduced fatigue, the core eugeroic effect.
- Sustained focus and concentration over extended work or study sessions.
- Enhanced motivation and drive, with users often reporting an easier time starting and staying on tasks.
- A subjectively “clean” quality of energy — described as smooth alertness without the jitteriness of caffeine or classic stimulants, and reportedly without a pronounced crash as the effect tapers.
These reports are broadly consistent with what modafinil users describe, which is unsurprising given the shared mechanism. But it bears repeating: subjective enhancement reports are vulnerable to placebo effects, selection bias and the simple fact that people who feel nothing are less likely to post about it. Treat these as community-reported impressions, not demonstrated outcomes.
Pharmacokinetics: onset, half-life and duration
This is one of the larger gaps in the flmodafinil picture, and you deserve a frank account of it. The human onset, half-life and duration of flmodafinil have not been measured and published. Figures you will see quoted — typically an onset of 30–60 minutes and a half-life “similar to modafinil” at around 12–15 hours — are extrapolations from the parent compound and from anecdote, not direct measurements of flmodafinil in people.
The rat microdialysis data hint at a longer-lasting effect than modafinil at the neurochemical level, and the fluorination chemistry provides a theoretical reason to expect slower metabolism. Both are reasonable grounds to hypothesise a long duration. Neither is a substitute for a proper human pharmacokinetic study. Active human metabolites of flmodafinil have likewise not been characterised in the public literature. In short: assume that the duration, peak timing and elimination of this compound in humans are genuinely uncertain, and dose with that uncertainty in mind.
Dosing and administration
There is no clinically validated human dose for flmodafinil. What follows is an account of what the community reports for educational purposes only — it is not a recommendation, and it cannot replace guidance from a qualified healthcare professional.
Because flmodafinil is claimed to be more potent per milligram than modafinil, users typically report dosing at roughly 25–50% of a comparable modafinil dose — in practical terms, around 25–100 mg, versus the 100–200 mg range for modafinil. Common community practice includes:
- Start low. Beginning at the bottom of the range (and lower still with an unfamiliar batch) to gauge individual sensitivity.
- Dose early. Taking it in the morning to avoid disrupting that night’s sleep, given the long presumed duration.
- Avoid stacking stimulants. Many users keep caffeine and other stimulants low or absent on dosing days to reduce overstimulation.
- Allow off-days. Intermittent rather than daily use is commonly favoured to limit tolerance and preserve effect.
A specific caution applies here: higher per-milligram potency means that small dosing errors carry outsized consequences. Combined with the absence of a validated dose and the variable accuracy of grey-market products, this makes careful measurement and conservative dosing especially important. A measured liquid format helps with precision, but it does not remove the underlying uncertainty.
Side effects and safety
The single most important safety statement is this: no human safety data for flmodafinil exists. Every safety claim about it is either anecdotal or extrapolated from modafinil. The correct mental model is “safety profile unknown”, not “proven safe”.
Anecdotally reported side effects mirror those of modafinil and include:
- Insomnia and sleep disruption — the most predictable effect for any wakefulness agent, particularly with late-day dosing.
- Headache, sometimes linked to dehydration.
- Anxiety, jitteriness or irritability.
- Reduced appetite and dry mouth.
- Gastrointestinal discomfort.
More seriously, certain risks documented for modafinil cannot be ruled out for flmodafinil by analogy. Modafinil carries a rare but serious risk of severe skin reactions (including Stevens-Johnson syndrome), psychiatric effects (anxiety, agitation, and rarely psychosis or mania), and elevations in heart rate and blood pressure. Whether flmodafinil shares these specific risks is genuinely unknown — and “unknown” means you cannot assume their absence.
On drug interactions, one of the compound’s most-promoted advantages is that, unlike modafinil, it reportedly does not induce CYP450 liver enzymes — which would in theory mean fewer interactions (modafinil, for example, can reduce the effectiveness of hormonal contraceptives). This is a preclinical, patent-derived claim that is unverified in humans. Do not rely on it. Combining flmodafinil with other stimulants, MAOIs, or serotonergic and cardiovascular medications is entirely unstudied and potentially hazardous.
Tolerance, dependence and withdrawal in humans are also uncharacterised. The low rodent abuse-liability signal is encouraging but does not guarantee that an unstudied analogue behaves the same way over time. Finally, there is a real-world hazard independent of the molecule itself: grey-market “research chemical” supply means purity, dosing accuracy and contamination are variable, and advertised purity figures such as “99%” are self-reported and frequently unverified. Flmodafinil is for adults only, and anyone considering it should consult a qualified healthcare professional first — particularly those with cardiovascular conditions, psychiatric history, or who are pregnant, breastfeeding or taking other medication.
Legal status in the EU
Flmodafinil sits in a genuine regulatory grey area across the European Union, and it is essential to understand this before considering any purchase. The key points:
- No marketing authorisation. It is not approved as a medicine by the EMA or any EU national regulator. It has no ATC code and is, formally, an unapproved investigational compound.
- No harmonised EU scheduling. Flmodafinil does not appear on a single EU-wide controlled-substances list, so its legal status varies from one member state to another.
- The “research chemical” label. It is widely sold online labelled “research chemical / not for human consumption” — a framing used specifically to sidestep medicines and consumer-safety regulation. That label does not make human use safe, nor does it reliably make it lawful.
- Stricter enforcement in some states. Germany, for instance, applies tougher import controls; flmodafinil could be treated there as an unlicensed medicinal product and/or scrutinised under novel-psychoactive-substance (NpSG) frameworks, and “research only” labelling does not reliably exempt it.
- Analogue scrutiny. Because modafinil itself is prescription-only across the EU, a close structural analogue marketed for cognitive effects can attract regulatory attention under medicines law or NPS provisions in several member states.
For context beyond the EU: in the USA it is unapproved and sold as a research chemical in a grey area; in the UK, sale for human consumption is likely unlawful under the Psychoactive Substances Act 2016; and in Australia it is an unapproved medicine not on the ARTG. The practical takeaway for an EU audience is blunt: there is no EU jurisdiction where flmodafinil is an approved, legal medicine. Legality of purchase and possession for personal use is uncertain and member-state-dependent, and the responsibility for understanding your local law rests with you.
Flmodafinil vs adrafinil vs armodafinil
It helps to place flmodafinil within the wider eugeroic family, because each relative tells you something about it by contrast.
vs Armodafinil
Armodafinil is the purified R-enantiomer of modafinil — approved, well-studied, and backed by full human pharmacokinetic, efficacy and safety data. Flmodafinil’s reported in-vitro DAT affinity (~4,090 nM) is marginally higher than armodafinil’s (~5,480 nM), but that single laboratory number is dwarfed by the difference in evidence quality. Armodafinil is a known quantity; flmodafinil is not.
vs Adrafinil
Adrafinil is a prodrug: the liver converts it into modafinil, which makes it slower in onset, weaker, and somewhat harder on the liver (it can raise liver enzymes). Flmodafinil is not a prodrug — it is claimed to act directly and more potently. The trade-off is instructive: adrafinil at least produces a known, studied active metabolite (modafinil), whereas flmodafinil’s human metabolites remain uncharacterised. Our adrafinil guide covers that compound’s effects, dosing and legality in detail.
Evidence-quality summary
Ranked by how well understood they are: modafinil and armodafinil are approved with robust human evidence; adrafinil is unapproved but well-understood as a prodrug of modafinil; and flmodafinil is the least-studied of the group, with no human trials and an evidence base limited to a handful of rodent and in-vitro studies plus marketing and anecdote. All four ultimately converge on atypical dopamine-reuptake inhibition with low rodent abuse-liability signals — flmodafinil’s distinction is structural and theoretical, not clinically demonstrated. You can browse the established options across our shop.
Who should — and should not — use it
Flmodafinil is an experimental compound, so any framing of “suitability” must be cautious. It is sometimes explored by healthy adults already familiar with the modafinil class who understand they are using an unapproved research chemical and accept the associated uncertainty and legal risk.
It is not appropriate for:
- Anyone under 18.
- People who are pregnant or breastfeeding.
- Those with cardiovascular conditions (high blood pressure, arrhythmias, heart disease), given the unstudied effects on heart rate and blood pressure.
- People with a history of anxiety, psychosis, mania or other psychiatric conditions.
- Anyone taking other medications — particularly stimulants, MAOIs, serotonergic drugs or cardiovascular medicines — where interactions are entirely unstudied.
- Anyone seeking treatment for a medical condition such as narcolepsy, ADHD, chronic fatigue or “long COVID”. Self-managing these with an unapproved compound risks delaying proper diagnosis and evidence-based care.
What the research does and doesn’t show
To bring the honest threads together: the research on flmodafinil does establish a clear chemical identity, a plausible dopamine-transporter mechanism with published in-vitro binding affinities, and a single rat microdialysis study showing meaningful, longer-lasting dopamine elevation that stays well below the levels seen with addictive stimulants. The fluorination chemistry gives genuine theoretical grounds to expect improved brain penetration and metabolic stability.
The research does not show that any of this translates into human cognitive enhancement, a defined dose, a measured half-life, or a verified safety profile. There are no human trials. The orexin and histamine effects are assumed, not demonstrated. The “cleaner, fewer interactions, more potent” claims are preclinical or anecdotal. Long-term safety, tolerance and dependence in humans are simply unknown. And the developer’s own apparent deprioritisation of the compound sits awkwardly with the “next-generation drug in development” framing used to market it. None of this means flmodafinil is worthless — it means an honest reader should treat it as a promising-but-unproven experimental compound, not an upgraded modafinil with established benefits. That clarity is, we think, the most useful thing we can offer.
Frequently asked questions
Is flmodafinil stronger than modafinil?
It is reported to be more potent per milligram — in-vitro binding data and user practice (dosing roughly 25–50% of a modafinil dose) point that way. But this is based on laboratory and rodent data plus anecdote, not human trials, so “stronger” should be read as an estimated claim rather than a proven fact.
How long does flmodafinil last?
Its human duration has never been measured and published. Commonly quoted figures of around 12–15 hours are extrapolated from modafinil. Rat data suggest a longer-lasting neurochemical effect than modafinil, but that is preclinical, not a measured human value.
Is flmodafinil legal in the EU?
There is no EU country where it is an approved medicine. It has no marketing authorisation, no harmonised scheduling, and is sold as a “research chemical”. Legality of purchase and possession for personal use is uncertain and varies by member state, with stricter enforcement in countries such as Germany.
What dose of flmodafinil should I take?
There is no clinically validated dose. Users anecdotally report 25–100 mg, dosed early in the day. Because per-milligram potency is claimed to be high, small errors matter — anyone considering it should start low and consult a qualified healthcare professional first.
Does flmodafinil have side effects?
No human safety data exists, so side effects are extrapolated from modafinil: insomnia, headache, anxiety, reduced appetite and dry mouth are reported. Rare but serious risks documented for modafinil (severe skin reactions, psychiatric effects, raised blood pressure) cannot be ruled out.
Is flmodafinil safer than modafinil?
This cannot be claimed. While preclinical data suggest it does not induce CYP450 enzymes — which might mean fewer drug interactions — that is unverified in humans. With no human safety studies, flmodafinil’s safety should be regarded as unknown, not superior.
How does flmodafinil compare to adrafinil and armodafinil?
Armodafinil is an approved, well-studied enantiomer of modafinil; adrafinil is an unapproved but understood prodrug that converts to modafinil in the liver. Flmodafinil is the least-studied of the group, with no human trials. See our adrafinil guide and modafinil vs armodafinil comparison for the established options.
Why is flmodafinil sold as a “research chemical”?
Because it has no medical approval anywhere, vendors label it “research chemical / not for human consumption” to operate outside medicines and consumer-safety regulation. This label does not make human use safe or clearly lawful — it is a regulatory workaround, not a safety endorsement.
Why is flmodafinil taken sublingually?
The sublingual route allows absorption directly into the bloodstream, partly bypassing first-pass liver metabolism, which can mean faster onset and easier dose titration. This is a general pharmacology principle; the specific human pharmacokinetics of flmodafinil by any route remain unpublished.
Has flmodafinil been approved by any regulator?
No. As of 2025 it is not approved by the EMA, FDA, MHRA or any other regulator for any use, and it has not completed published human clinical trials. Its developer has reportedly deprioritised it in favour of a different compound.
The bottom line
Flmodafinil is one of the most intriguing compounds in the eugeroic family — a thoughtfully engineered, fluorinated relative of modafinil with a plausible mechanism and a genuinely loyal community following. But intrigue is not evidence. The figures so often repeated about it — the potency multipliers, the duration claims, the “cleaner” profile — are estimates and anecdotes, not human findings, and the entire compound remains unapproved and under-studied across the EU and beyond. If you choose to explore the established end of this category, our modafinil and armodafinil ranges are backed by far more research, and you can compare your options in our shop. Whatever you decide, decide it with clear eyes and good information.
This article is for educational purposes only and is not medical advice. Flmodafinil is an unapproved compound with no human clinical data; nothing here is intended to diagnose, treat, cure or prevent any condition. It is intended for adults only. Always consult a qualified healthcare professional before using any nootropic, and ensure you understand the legal status of any compound in your country.
